Sandoz drives differentiated portfolio with deal to commercialize new treatment for Opioid-Induced Constipation in key European countries
- Agreement with Shionogi to commercialize Rizmoic? (naldemedine) in Germany, UK and Netherlands, plus right of first refusal for certain other European markets
- Rizmoic??is an innovative medicine for treating constipation caused by opioid pain relief medicines, in patients who have previously been treated with a laxative
- Agreement reinforces Sandoz anti-pain franchise and commitment to pioneer access to healthcare in areas of unmet medical need